Bank of Stockton raised its stake in Abbott Laboratories (NYSE:ABT) by 32.5% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 18,643 shares of the healthcare product maker’s stock after acquiring an additional 4,568 shares during the quarter. Bank of Stockton’s holdings in Abbott Laboratories were worth $994,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also modified their holdings of the company. Teacher Retirement System of Texas grew its position in shares of Abbott Laboratories by 17.7% during the 3rd quarter. Teacher Retirement System of Texas now owns 785,211 shares of the healthcare product maker’s stock worth $41,899,000 after buying an additional 117,890 shares during the period. Rhumbline Advisers grew its position in shares of Abbott Laboratories by 1.0% during the 3rd quarter. Rhumbline Advisers now owns 3,042,445 shares of the healthcare product maker’s stock worth $162,345,000 after buying an additional 30,654 shares during the period. Advisor Group Inc. grew its position in shares of Abbott Laboratories by 3.4% during the 3rd quarter. Advisor Group Inc. now owns 134,641 shares of the healthcare product maker’s stock worth $7,185,000 after buying an additional 4,477 shares during the period. Moody Lynn & Lieberson LLC grew its position in shares of Abbott Laboratories by 17.1% during the 3rd quarter. Moody Lynn & Lieberson LLC now owns 326,468 shares of the healthcare product maker’s stock worth $17,420,000 after buying an additional 47,610 shares during the period. Finally, First National Trust Co. grew its position in shares of Abbott Laboratories by 5.7% during the 3rd quarter. First National Trust Co. now owns 78,658 shares of the healthcare product maker’s stock worth $4,197,000 after buying an additional 4,224 shares during the period. Institutional investors own 71.15% of the company’s stock.

Several research analysts recently weighed in on the stock. Barclays reissued a “buy” rating and set a $66.00 price objective on shares of Abbott Laboratories in a research note on Monday. Royal Bank of Canada reissued a “buy” rating and set a $65.00 price objective on shares of Abbott Laboratories in a research note on Tuesday. Zacks Investment Research raised shares of Abbott Laboratories from a “hold” rating to a “buy” rating and set a $64.00 price objective on the stock in a research note on Tuesday, January 2nd. Evercore ISI assumed coverage on shares of Abbott Laboratories in a research note on Wednesday, January 3rd. They set an “outperform” rating and a $64.00 price objective on the stock. Finally, Morgan Stanley raised shares of Abbott Laboratories from an “equal weight” rating to an “overweight” rating and set a $67.00 price objective on the stock in a research note on Tuesday, January 2nd. Six research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus price target of $60.24.

In related news, insider Daniel Gesua Sive Salvadori sold 71,157 shares of the business’s stock in a transaction on Tuesday, November 14th. The shares were sold at an average price of $55.00, for a total transaction of $3,913,635.00. Following the transaction, the insider now directly owns 144,955 shares in the company, valued at $7,972,525. The sale was disclosed in a filing with the SEC, which is available through this link. Also, Chairman Miles D. White sold 276,886 shares of the business’s stock in a transaction on Wednesday, December 6th. The stock was sold at an average price of $54.41, for a total transaction of $15,065,367.26. Following the transaction, the chairman now owns 3,677,913 shares in the company, valued at $200,115,246.33. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 501,172 shares of company stock worth $27,533,150. 0.76% of the stock is owned by corporate insiders.

Shares of Abbott Laboratories (NYSE:ABT) opened at $58.95 on Friday. The company has a quick ratio of 2.26, a current ratio of 2.69 and a debt-to-equity ratio of 0.72. The company has a market cap of $102,610.00, a price-to-earnings ratio of 48.72, a PEG ratio of 1.88 and a beta of 1.55. Abbott Laboratories has a 1 year low of $39.25 and a 1 year high of $59.60.

Abbott Laboratories (NYSE:ABT) last announced its quarterly earnings data on Wednesday, October 18th. The healthcare product maker reported $0.66 EPS for the quarter, topping the Zacks’ consensus estimate of $0.65 by $0.01. The business had revenue of $6.83 billion for the quarter, compared to analyst estimates of $6.72 billion. Abbott Laboratories had a net margin of 8.37% and a return on equity of 13.98%. The firm’s revenue for the quarter was up 28.8% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.59 earnings per share. research analysts forecast that Abbott Laboratories will post 2.5 EPS for the current year.

The company also recently announced a quarterly dividend, which will be paid on Thursday, February 15th. Investors of record on Friday, January 12th will be issued a dividend of $0.28 per share. This represents a $1.12 dividend on an annualized basis and a yield of 1.90%. This is an increase from Abbott Laboratories’s previous quarterly dividend of $0.27. The ex-dividend date of this dividend is Thursday, January 11th. Abbott Laboratories’s payout ratio is presently 87.60%.

TRADEMARK VIOLATION NOTICE: This piece was first posted by Daily Political and is owned by of Daily Political. If you are accessing this piece on another domain, it was copied illegally and reposted in violation of US & international copyright laws. The correct version of this piece can be read at https://www.dailypolitical.com/2018/01/12/bank-of-stockton-boosts-holdings-in-abbott-laboratories-abt.html.

Abbott Laboratories Company Profile

Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. Its Established Pharmaceutical Products include a range of branded generic pharmaceuticals manufactured around the world and marketed and sold outside the United States.

Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT).

Institutional Ownership by Quarter for Abbott Laboratories (NYSE:ABT)

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.